Truveta (@truveta) header
Truveta (@truveta) profile picture

Truveta

@truveta

Truveta delivers the most complete, timely, and clean regulatory-grade EHR data for scientifically rigorous research. Our mission is Saving Lives with Data.

 Seattle area, Washington
Truveta.com
Joined October 2017
  • Tweets2.2K
  • Following1K
  • Followers2K
1.1KMedia
Photo by Truveta (@truveta)Photo by Truveta (@truveta)Photo by Truveta (@truveta)Photo by Truveta (@truveta)Photo by Truveta (@truveta)Photo by Truveta (@truveta)Photo by Truveta (@truveta)Photo by Truveta (@truveta)Photo by Truveta (@truveta)Photo by Truveta (@truveta)
💡 GLP-1s now account for more than 8% prescriptions in the US. The latest GLP-1 monitoring report, updated through September 2026, shows how quickly the landscape is moving: 📈 Anti-obesity prescribing increased right after the launch of Medicare GLP-1 Bridge program 💉 Tirzepatide prescribing grew 11% in three months and remains the most prescribed GLP-1 medication 💊 Orforglipron (Foundayo pill) prescribing more than doubled after its April approval Dive into the analysis: tr.vet/4sMs0Jp
The line graph titled "Rate of first-time GLP-1 prescribing over time, by age" shows trends from 2019 to 2023 for four age groups: 18-34, 35-49, 50-64, and 65+ years. Key events include the "Medicare GLP-1 Bridge launch" in early 2023, which corresponds with an uptick in prescribing rates. The data is sourced from Trueta.com.

ALT The line graph titled "Rate of first-time GLP-1 prescribing over time, by age" shows trends from 2019 to 2023 for four age groups: 18-34, 35-49, 50-64, and 65+ years. Key events include the "Medicare GLP-1 Bridge launch" in early 2023, which corresponds with an uptick in prescribing rates. The data is sourced from Trueta.com.

31
📍 Heading to #AMIA2026 in Dallas? Join Clinical Terminologist Jamalynne Deckard, MS on Monday, November 9 as she shares insights on the syntactic and semantic normalization of more than 2.5M cancer staging records. Researchers used our LLM, TLM-Oncology, to extract staging data from clinical notes across all solid tumors, then normalized it to SNOMED CT in the Truveta Data Model. The result is a consistent, research-ready dataset for health system, academic, government, and life science researchers. We hope to see you at @AMIAinformatics!
A presentation slide titled "Research presentation" with the text "Syntactic and semantic normalization of >2.5M cancer staging records." The event details are Monday, November 9, 5:00-6:30pm CDT in Dallas, Texas. Logos for Truveta and AMIA are at the bottom. A photo of Jamalynne Deckard, MS, a Clinical Terminologist at Truveta, is on the right.

ALT A presentation slide titled "Research presentation" with the text "Syntactic and semantic normalization of >2.5M cancer staging records." The event details are Monday, November 9, 5:00-6:30pm CDT in Dallas, Texas. Logos for Truveta and AMIA are at the bottom. A photo of Jamalynne Deckard, MS, a Clinical Terminologist at Truveta, is on the right.

1
41
New research from #EASD2026: Adults with type 2 diabetes on basal insulin who used CGM had a 45% lower mortality risk at one year and 36% lower at two years, plus lower risk of heart attack, stroke, and hospitalization. Using target trial emulation, the analysis of 28,000 patients within Truveta Data adds to the evidence that the value of CGMs may extend well beyond glucose control. Swipe through for the highlights, and dive into the findings: tr.vet/4kvnyfZ
Image from Truveta (@truveta)
Image from Truveta (@truveta)
Image from Truveta (@truveta)
Image from Truveta (@truveta)
28
Since its launch on July 1, the Medicare GLP-1 Bridge program expanded access to GLP-1 medications for seniors by reducing out-of-pocket costs. Three months later, new findings from Truveta Research show GLP-1 prescribing among adults aged 65+ remains elevated: ➡️ GLP-1 prescribing was 20.6% higher in September compared to June ➡️ First-time GLP-1 prescriptions was up 21.3% ➡️ Tirzepatide (Zepbound) prescribing rose 71.1% and semaglutide (Wegovy) prescribing rose 32.8% Read the full analysis: tr.vet/48wOJ2M
A line graph titled "Rate of GLP-1 prescribing over time, by age" shows data from 2019 to 2026. The graph includes four lines representing different age groups: 18-34, 35-49, 50-64, and 65+ years. Each line depicts an upward trend in GLP-1 prescribing rates over time. A vertical line marks the "Medicare GLP-1 Bridge launch" in 2024. The source is Truveta.com.

ALT A line graph titled "Rate of GLP-1 prescribing over time, by age" shows data from 2019 to 2026. The graph includes four lines representing different age groups: 18-34, 35-49, 50-64, and 65+ years. Each line depicts an upward trend in GLP-1 prescribing rates over time. A vertical line marks the "Medicare GLP-1 Bridge launch" in 2024. The source is Truveta.com.

1
64
Rare diseases have historically been difficult to study in real-world care, and new research using Truveta Data is helping change that 🔎 A study published in the Orphanet Journal of Rare Diseases characterized 214 patients with ornithine transcarbamylase deficiency (OTCD), a rare genetic disorder. Researchers combined longitudinal EHR data with symptoms and clinical details extracted from physician notes not captured in structured data to create a more complete view and advance care for this rare patient population. Read the research: tr.vet/4zjtM7n
The image features the Truveta logo, the text "The real-world burden of OTCD," and a background of a leaf with water droplets. It mentions the "Orphanet Journal of Rare Diseases.

ALT The image features the Truveta logo, the text "The real-world burden of OTCD," and a background of a leaf with water droplets. It mentions the "Orphanet Journal of Rare Diseases.

1
1
70
Nothing spooky about these new Truvetans 🎃 Welcome to the team! We couldn't be more grateful to have you on the team 💙
A group photo of thirteen individuals with a blue background and photos arranged in a collage format. Each photo is labeled with names and titles. At the top, text reads "Welcome new Truvetans!" The Truveta logo is at the bottom right corner.

ALT A group photo of thirteen individuals with a blue background and photos arranged in a collage format. Each photo is labeled with names and titles. At the top, text reads "Welcome new Truvetans!" The Truveta logo is at the bottom right corner.

44
📣 Live from IMPACCT RWE in Boston: VP of Partnerships Conor Wyand shared how Truveta is shortening the time to insight, giving researchers a faster way to spot emerging trends, explore new questions, and turn what they learn into trusted evidence. It’s a new way of approaching real-world research: learn faster, ask better questions, and ultimately generate evidence that can improve healthcare.
Image from Truveta (@truveta)
37
Our IDC team in Hyderabad continues to grow! Join us in giving them a warm welcome 👏
Welcome poster featuring six individuals joining Truveta's IDC team. Each person's name, job title, and a headshot are displayed. The background shows a forest scene. Truveta's logo is at the bottom.

ALT Welcome poster featuring six individuals joining Truveta's IDC team. Each person's name, job title, and a headshot are displayed. The background shows a forest scene. Truveta's logo is at the bottom.

36
📣 Today at AMCP Nexus in San Diego: Director of Research Brianna Cartwright, MS shared an updated look at early uptake of oral semaglutide for obesity (Wegovy pill) using Truveta Data from more than 182,000 patients through September 2026. Dive into the findings: tr.vet/4jLp4KP #AMCPNexus @amcporg
Image from Truveta (@truveta)
1
1
102
🫀 When someone is hospitalized for heart failure, doctors work to remove extra fluid. But how intensive does that treatment need to be? A new study in the Journal of Cardiac Failure (@JCardFail) used Truveta Data to look at more than 109,000 heart failure hospitalizations across US health systems. They found that more intensive diuretic treatment removed more fluid, but it wasn’t linked to fewer readmissions or deaths within 90 days. Patients who lost more weight did have lower odds of those outcomes, whichever treatment they got. Read the research: tr.vet/3WcAspb
Comparing treatment strategies in heart failure hospitalization

Comparing treatment strategies in heart failure hospitalization

A study using Truveta Data examined diuretic treatment strategies in more than 109,000 patients hospitalized for heart failure and associated outcomes.

truveta.com
53
#ISPOREurope 2026 is almost here, and we’re excited to share the research Truveta will be presenting in Vienna 📍 From characteristics of patients treated with GLP-1s to food insecurity and blood pressure control, this year’s posters show how real-world data can help answer important questions across healthcare and accelerate evidence generation at scale. See the full poster schedule in the images below. Make sure to stop by our booth (#1222) or schedule time with our on-site team: tr.vet/4ejxDJl @ISPORorg
The image is a conference poster for ISPOR Europe 2026 and Truveta. It details a research presentation on depression severity changes following the initiation of GLP-1 vs non-GLP-1 anti-obesity medications using real-world data. The session is scheduled for Monday, November 9, from 16:00 to 19:00. The lead author is Claire Campbell, PhD, Partner Facing Research Scientist.

ALT The image is a conference poster for ISPOR Europe 2026 and Truveta. It details a research presentation on depression severity changes following the initiation of GLP-1 vs non-GLP-1 anti-obesity medications using real-world data. The session is scheduled for Monday, November 9, from 16:00 to 19:00. The lead author is Claire Campbell, PhD, Partner Facing Research Scientist.

A promotional poster for ISPOR Europe 2026 and Truveta. The poster details a session titled "Profiles among adults with obesity treated with GLP-1 vs non-GLP-1 anti-obesity medications using real-world data." The session is scheduled for Tuesday, November 10, from 10:30 to 13:30. An image of the lead author, Claire Campbell, PhD, is shown at the bottom.

ALT A promotional poster for ISPOR Europe 2026 and Truveta. The poster details a session titled "Profiles among adults with obesity treated with GLP-1 vs non-GLP-1 anti-obesity medications using real-world data." The session is scheduled for Tuesday, November 10, from 10:30 to 13:30. An image of the lead author, Claire Campbell, PhD, is shown at the bottom.

Poster for ISPOR Europe 2026 sponsored by Truveta. The poster is titled "Food insecurity and antihypertensive medication adherence among adults with hypertension." The session is on Tuesday, November 10, from 10:30 to 13:30. The lead author is Amy Austin, MHI, Partner Facing Research Scientist.

ALT Poster for ISPOR Europe 2026 sponsored by Truveta. The poster is titled "Food insecurity and antihypertensive medication adherence among adults with hypertension." The session is on Tuesday, November 10, from 10:30 to 13:30. The lead author is Amy Austin, MHI, Partner Facing Research Scientist.

The image is a promotional flyer for a poster session at ISPOR Europe 2026, sponsored by Truveta. The session is titled "Antihypertensive prescribing patterns and blood pressure control in adults with food insecurity." It will take place on Tuesday, November 10, from 16:00 to 19:00. The lead author is Amy Austin, MHI, a partner-facing research scientist. There is a photo of Amy Austin in the bottom corner.

ALT The image is a promotional flyer for a poster session at ISPOR Europe 2026, sponsored by Truveta. The session is titled "Antihypertensive prescribing patterns and blood pressure control in adults with food insecurity." It will take place on Tuesday, November 10, from 16:00 to 19:00. The lead author is Amy Austin, MHI, a partner-facing research scientist. There is a photo of Amy Austin in the bottom corner.

61
#ISPOREurope 2026 is just around the corner, and interim co-CEO, Chief Medical Officer, and co-founder Ryan Ahern, MD, MPH will share how AI-enabled, real-time insights can drive evidence strategy in a live session. Stop by the session on Monday, 11/9 at 15:15 CET, and be sure to visit our booth (#1222) to meet the on-site team: tr.vet/3Wzu1fT @ISPORorg
Image from Truveta (@truveta)
49
Robotic-assisted hip replacements have nearly tripled in the US, from 3.8% of procedures in 2018 to 10.8% in 2026. The latest analysis from Truveta Research looked at more than 259,000 total hip replacements to see how outcomes compare when robotic assistance is used. Explore the outcomes in the full analysis: tr.vet/4yFQGVw
55
📍 Heading to #AMCPNexus in San Diego? Join Director of Research Brianna Cartwright, MS on Wednesday, October 28 for insights on early uptake of oral semaglutide for obesity (the Wegovy pill). The Truveta Research team looked at nearly 49,000 patients who received a prescription or fill after FDA approval. A preview of what we found: ➡️ Most patients with a recent encounter had no prior evidence of GLP-1 therapy ➡️ Among patients with prescriber data available, most received the prescription from a general practice provider We hope to see you there! @amcporg
This image is a promotional announcement for a research presentation titled "Early uptake of oral semaglutide for obesity" by Brianna Cartwright, MS, who is the Director of Research at Truveta. The event is scheduled for Wednesday, October 28 at 12pm PST in San Diego, California. Logos for Truveta, AMCP, and Nexus are displayed.

ALT This image is a promotional announcement for a research presentation titled "Early uptake of oral semaglutide for obesity" by Brianna Cartwright, MS, who is the Director of Research at Truveta. The event is scheduled for Wednesday, October 28 at 12pm PST in San Diego, California. Logos for Truveta, AMCP, and Nexus are displayed.

2
105
Linking genomic data with clinical data can help us unlock profound insights into how genetics affect health. The goal of the Truveta Genome Project is to transform human health by impacting how diseases are prevented, diagnosed, and cured. Hear from Senior Director of Genomics Kristin Rand, PhD, MPH on what makes our approach unique: the breadth and depth of the clinical and genomic data, the real-time view of the patient journey, and health systems as partners at the center of it all: tr.vet/4dpQFM9
1
53
The Truveta Genome Project aspires to create the largest and most diverse de-identified database of genotypic and phenotypic information ever assembled. And today, we are enrolling patients and collecting samples. 🧬 In her latest perspective, Kristin Rand, PhD, MPH reflects on the months of building the foundation for a consented, de-identified genomic dataset linked with longitudinal clinical data, created in collaboration with participating health systems. She shares why context is what gives genomics its power, how health systems lead enrollment and informed consent to honor patient trust, and why representation at scale matters for discoveries that benefit all patients. Read the full perspective: tr.vet/3VZJ7v1
60
🇦🇹 Headed to Vienna for #ISPOREurope? Stop by booth #1222 to see how Truveta’s health system-owned data and intelligence platform supports real-world evidence generation with continuously updated clinical data, feasibility studies, and more. We can't wait to connect with leaders in HEOR and discuss how high-quality real-world data can help generate the evidence that informs better decisions for patients. Don’t forget to book time with our on-site team here: tr.vet/3Wzu1fT @ISPORorg
TruVeta advertisement for ISPOR Europe 2026 with a scenic view of Vienna, Austria. The event is from November 8-11. Attendees are invited to visit booth #1222 for a demo, feasibility studies, and more.

ALT TruVeta advertisement for ISPOR Europe 2026 with a scenic view of Vienna, Austria. The event is from November 8-11. Attendees are invited to visit booth #1222 for a demo, feasibility studies, and more.

57
Robotic assistance is becoming a much bigger part of knee replacement surgery. Truveta Research examined how its use has changed and how outcomes compare: ➡️ Across more than 360,000 knee replacements, use of robotic assistance nearly tripled, rising from 12.4% of procedures in 2018 to 36.1% in 2026. ➡️ Robotic-assisted procedures took longer, but were associated with lower rates of several short- and long-term postoperative complications after adjustment for patient and clinical characteristics. Dive into the findings: tr.vet/47M1RAI
63
Healthcare generates valuable knowledge every day through patient encounters, clinical insights, and research discoveries. But too often, that knowledge remains fragmented within individual institutions, slowing opportunities to improve care. 🔎 A learning health system creates a path for those insights to travel farther. By connecting clinical, genomic, and imaging data, researchers can develop a more complete understanding of patients, disease, treatments, and outcomes. Our latest perspective from President and Chief Scientific Officer Johnathan Lancaster, MD, PhD explores why learning together may be healthcare’s greatest innovation and how collaboration helps healthcare learn faster: tr.vet/3Wsj7bO
49
Today, we're thrilled to see Truveta ranked #4 on the 2026 @LinkedIn Top Startups list in Seattle 👏 Seattle has long been a hub for technological innovation, and Truveta has had its roots in the Pacific Northwest since the beginning. From the foundation we’ve built in Seattle to our global team around the world, we’re deeply grateful for the contributions of each and every Truvetan furthering our mission of Saving Lives with Data. We’re honored to featured on this list for third year in a row, and we can’t wait to see where the future takes us 🚀 Learn more: tr.vet/4e6s9kQ
The image features a blue and green gradient background with the text "Truveta recognized as LinkedIn Top Startup in Seattle." On the right, there is a badge with a rocket icon and text: "LinkedIn Top Startups 2026 Seattle.

ALT The image features a blue and green gradient background with the text "Truveta recognized as LinkedIn Top Startup in Seattle." On the right, there is a badge with a rocket icon and text: "LinkedIn Top Startups 2026 Seattle.

54
Load more